Ingenza is redefining drug substance development with its inGenius® platform
We deliver scalable, efficient and ICH-compliant bioprocesses for our customer IND applications. Built on decades of experience, our inGenius® platform has been developed with a focus on improving efficiency and de-risking future processes by enhancing four key modules: Strain/Cell-line Development; Process Development; Analytical Development and Manufacture of pre-clinical material.
Our platform is modality-agnostic and has successfully been applied to the recombinant expression of complex proteins, peptides, monoclonal and VHH antibodies, enzymes and subunit vaccines.
You can read more about these components below.